RXI Pharma (RXII) Reports Q2 Loss of $0.11/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RXi Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
August 10, 2017 7:05 AM EDTMARLBOROUGH, Mass., Aug. 10, 2017 /PRNewswire/ --Â RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today reported its financial results for the second quarter ended June 30, 2017, and provided a business update.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
"During the first half of 2017, the Company focused on the main elements that can drive progress and value for RXi," said Dr. Geert... More
